(Q48238606)

9 February 2018

title

Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. (English)

1 reference

9 February 2018

main subject

fluticasone propionate

1 reference

J T Li

1

1 reference

9 February 2018

M F Goldstein

2

1 reference

9 February 2018

G N Gross

3

1 reference

9 February 2018

M J Noonan

4

1 reference

9 February 2018

S Weisberg

5

1 reference

9 February 2018

L Edwards

6

1 reference

9 February 2018

K D Reed

7

1 reference

9 February 2018

P R Rogenes

8

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 April 1999

1 reference

9 February 2018

The Journal of Allergy and Clinical Immunology

published in

1 reference

9 February 2018

volume

103

1 reference

9 February 2018

issue

4

1 reference

9 February 2018

page(s)

622-629

1 reference

9 February 2018

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

How should inhaled glucocorticoids be compared?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Normal and abnormal function of the hypothalamic-pituitary-adrenocortical system in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

High-dose inhaled steroids in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Assessment of the relative systemic potency of inhaled fluticasone and budesonide.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Standardization of spirometry: a summary of recommendations from the American Thoracic Society. The 1987 update

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis--which tests should be used?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970234-4

7 January 2021

10.1016/S0091-6749(99)70234-4

Identifiers

DOI

1 reference

9 February 2018

1 reference

9 February 2018